Changes to Novavax executive leadership team

US biotech Novavax (Nasdaq: NVAX), which is advancing protein-based vaccines with its Matrix-M adjuvant, has announced changes to its executive leadership team.

Already a long-time executive of the firm, John Trizzino will take on the newly created role of president and chief operating officer of Novavax. In this role, Mr. Trizzino will lead the commercial; chemistry, manufacturing and controls or CMC; and regulatory functions. He will continue to serve on the company's executive leadership team.

Mr Trizzino has broad experience in publicly held companies and over 25 years in the vaccines market. During his 12 years with Novavax, Mr Trizzino most recently served as executive vice president, chief commercial officer and chief business officer, and has also held the roles of chief financial officer, senior VP of commercial operations and SVP of business development.